Scarica l'app Stockscreener
6.21
11.49%
0.64
Sagimet Biosciences Inc Borsa (SGMT) Ultime notizie
Sagimet Biosciences: Advancing FASN Inhibitor Pipeline and Multi-Indication Opportunities Support Buy Rating and $26 Target - TipRanks
Why Sagimet Biosciences Inc. stock remains on watchlistsJuly 2025 Recap & AI Powered Market Entry Strategies - ulpravda.ru
After-Hours Biotech Gainers: RVMD Soars On Merck Deal Talks Reports, SXTC, KALV, SGMT Rally - RTTNews
How Sagimet Biosciences Inc. stock performs in stagflationJuly 2025 Fed Impact & Verified Short-Term Plans - ulpravda.ru
Why retail investors favor Sagimet Biosciences Inc. stockQuarterly Investment Review & AI Based Buy and Sell Signals - ulpravda.ru
Why Sagimet Biosciences Inc. stock could be next big winnerRisk Management & Reliable Breakout Forecasts - ulpravda.ru
Can Sagimet Biosciences Inc. stock beat market expectations this quarterJuly 2025 PreEarnings & AI Driven Price Forecasts - ulpravda.ru
Published on: 2026-01-08 19:16:00 - ulpravda.ru
Study links experimental drug to improved liver fibrosis in MASH patients - Stock Titan
Falcon Technoprojects India Limited Chart Enters High Volatility ZoneTake Profit Strategies & Fast Growing Trading Ideas - earlytimes.in
Sagimet Biosciences Inc. (SGMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely - Yahoo Finance
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Disc Medicine (IRON) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $26 - 富途牛牛
Sagimet rises as licensing deal with Teva unit targets Madrigal drug - MSN
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts - TipRanks
Why Sagimet Biosciences Inc. stock could rally in 2025Gap Up & Verified Entry Point Detection - Улправда
Sagimet Biosciences (NASDAQ:SGMT) Stock Price Up 5.4%Still a Buy? - MarketBeat
Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT) - Seeking Alpha
Can Sagimet Biosciences Inc. stock maintain growth trajectoryJuly 2025 Levels & Daily Entry Point Trade Alerts - DonanımHaber
Sagimet reports positive Phase 1 results for MASH combination therapy By Investing.com - Investing.com Australia
How Sagimet Biosciences Inc. stock performs in high volatility marketsPrice Action & Low Volatility Stock Suggestions - DonanımHaber
Guidance Update: Why Sagimet Biosciences Inc. stock could be next big winner - Улправда
How Sagimet Biosciences Inc. (0O2) stock compares with top peersWeekly Investment Summary & Daily Chart Pattern Signals - Улправда
Investment Review: Why Sagimet Biosciences Inc. stock could be next big winnerMarket Sentiment Review & Fast Exit and Entry Trade Guides - Улправда
Sagimet Highlights Positive MASH Combo Data and Pipeline Progress - TipRanks
Sagimet reports positive Phase 1 results for MASH combination therapy - Investing.com India
Sagimet Biosciences Announces Positive Phase 1 PK Trial Results - TradingView — Track All Markets
[8-K] Sagimet Biosciences Inc. Reports Material Event | SGMT SEC FilingForm 8-K - Stock Titan
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination - The Manila Times
Sagimet Biosciences Announces Positive Results from the - GlobeNewswire
Sagimet Biosciences (Nasdaq:SGMT) Secures Global License for Resmetirom API in Combination Program - Kalkine Media
Sagimet Biosciences enters global license agreement with TAPI - MSN
Strategic Licensing and Pipeline Advancements Drive Buy Rating for Sagimet Biosciences - TipRanks
Sagimet Biosciences Signs License Agreement With Teva Subsidiary for Resmetirom Development - marketscreener.com
TEVA's Subsidiary Grants License to Sagimet for Innovative Drug Development - GuruFocus
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program - The Manila Times
Sagimet Biosciences Inc Enters License Agreement with TAPI - TradingView — Track All Markets
Sagimet Biosciences (NASDAQ: SGMT) signs TAPI deal for resmetirom API combo - Stock Titan
Sagimet Biosciences and TAPI Announce Global License - GlobeNewswire
Sagimet Biosciences Earnings Notes - Trefis
What the Technical Setup Suggests for HCKK Ventures Limited in the Next 30 Days - earlytimes.in
Liver Fibrosis Market Expected to Gain Momentum Through 2034, According to DelveInsight | Madrigal Pharma, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio - Barchart.com
Sagimet Biosciences announces China’s NMPA accepted NDA for denifanstat - MSN
Sagimet's license partner Ascletis announced acceptance of new drug application for Denifanstat - marketscreener.com
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration - The Manila Times
Sagimet Biosciences Licenses Denifanstat for Acne Treatment to Ascletis Pharma as NMPA Accepts NDA in China - Quiver Quantitative
Sagimet Biosciences (Nasdaq: SGMT) sees China partner’s acne drug NDA accepted by NMPA - Stock Titan
SGMTSagimet Biosciences Inc. Latest Stock News & Market Updates - Stock Titan
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):